Novozymes Biopharma Enters Agreement with a Leading Vaccine Company
![](/46/pdcnewsitem/03/33/78/kEDOOAfanw4FAUW.png)
Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.
“This collaborative research agreement with one of the leading vaccine companies showcases the potential application of Novozymes’ proven albumin-based half-life extension technology in the vaccine space”, says Svend Licht, Global Head of Sales & Business Development, Novozymes Biopharma. He continues, “The Veltis technology could overcome many of the limitations of current subunit vaccines, resulting in both improved healthcare and economic outcomes.”
The human immune system's capability to respond effectively to replicating viruses means that some live attenuated vaccines are effective with a single dose. Subunit vaccines are regarded as a safer and more specific alternative to live attenuated vaccines; however, they are often limited by the requirement for multiple dosing and the need for adjuvants to improve the immune response.
Novozymes Biopharma’s Albumin vaccine complex technology, based on the genetic fusion or conjugation of a subunit antigen to Novozymes’ sequence modified albumin variants, has been specifically designed to overcome these limitations by allowing the fused or conjugated antigenic species to remain in circulation for a longer period of time than the uncomplexed antigen.
Veltis’ long half-life is due to a receptor mediated recycling process in the cells lining blood vessels. In specific immune cells, this receptor has been shown to facilitate presentation of antigens when bound to antibodies as a complex. The Albumin vaccine complex technology should similarly be presented in these immune cells, potentially eliciting a powerful and protective immune response.
The agreement covers a feasibility study between the parties and is not expected to have any impact on Novozymes’ financial results in 2014. Recently Novozymes also announced that its half-life extension technology is being used by Janssen and GlaxoSmithKline.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance